Education
About Us
Working with TipRanks
Follow Us
Accelerate Diagnostics (AXDX)
NASDAQ:AXDX
Top Page
Accelerate Diagnostics
(NASDAQ:AXDX)
34Underperform
Accelerate Diagnostics (AXDX) vs. S&P 500 (SPY)
Market Cap
$12.86M
Dividend YieldN/A
Average Volume (3M)58.68K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth-2.99%
EPS Growth59.87%
CountryUS
Employees107
SectorHealthcare
Sector Strength74
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.21
Shares Outstanding25,210,392
10 Day Avg. Volume21,165
30 Day Avg. Volume58,678
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap6.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.77
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Accelerate Diagnostics Business Overview & Revenue Model
Company DescriptionAccelerate Diagnostics, Inc. (AXDX) is a medical diagnostics company specializing in the development and commercialization of innovative solutions aimed at improving patient outcomes through the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's flagship product, the Accelerate Pheno system, is designed to significantly reduce the time needed to deliver crucial diagnostic results in clinical microbiology laboratories, thereby facilitating faster and more effective treatment decisions in the healthcare sector.
How the Company Makes MoneyAccelerate Diagnostics generates revenue primarily through the sale of its diagnostic systems and associated consumables. The company's primary revenue stream comes from the Accelerate Pheno system, including initial hardware sales and ongoing sales of proprietary consumable test kits required for each diagnostic test conducted. Additionally, Accelerate Diagnostics may engage in service agreements and maintenance contracts with healthcare institutions to provide continuous support and updates for their diagnostic systems. Strategic partnerships and collaborations with healthcare providers and laboratories also play a role in expanding their market reach and enhancing their revenue potential.
Accelerate Diagnostics Financial Statement Overview
Summary
Accelerate Diagnostics is in a precarious financial position with declining revenues, substantial losses, and high leverage. The negative stockholders' equity and ongoing cash burn present significant financial risks.Income Statement
The company has consistently faced declining revenues over the past years with negative EBIT and EBITDA margins, indicating operational inefficiencies. The gross and net profit margins are negative, reflecting ongoing losses and cost management issues. There is a lack of revenue growth and profitability, which presents significant challenges.35
Negative
Balance Sheet
The balance sheet shows high leverage with a negative stockholders' equity, resulting in an unfavorable debt-to-equity ratio. This indicates financial instability and potential insolvency risks. The equity ratio is negative, signifying that liabilities exceed assets, which is concerning for investors and creditors.20
Very Negative
Cash Flow
The company reports negative free cash flow, although there is a slight improvement in operational cash flow compared to previous years. However, the high reliance on financing activities to support operations is unsustainable in the long term. The operating cash flow to net income ratio is negative, reflecting ongoing cash burn.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 11.70M | 12.06M | 12.75M | 11.78M | 11.16M | Gross Profit |
| 2.70M | 2.55M | 3.30M | -381.00K | 4.46M | EBIT |
| -35.31M | -54.03M | -62.80M | -71.56M | -63.70M | EBITDA |
| -33.57M | -49.77M | -55.80M | -59.59M | -59.66M | Net Income Common Stockholders |
| -50.05M | -61.62M | -62.49M | -77.70M | -78.21M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 15.10M | 13.22M | 45.56M | 63.62M | 68.27M | Total Assets |
| 28.56M | 31.37M | 65.02M | 83.05M | 93.42M | Total Debt |
| 63.35M | 39.22M | 77.54M | 111.11M | 149.98M | Net Debt |
| 48.25M | 27.08M | 42.63M | 71.22M | 114.20M | Total Liabilities |
| 84.60M | 51.25M | 87.28M | 118.12M | 156.24M | Stockholders Equity |
| -56.04M | -19.89M | -22.26M | -35.07M | -62.81M |
| Cash Flow | Free Cash Flow | |||
| -24.19M | -41.23M | -49.28M | -47.93M | -51.76M | Operating Cash Flow |
| -24.19M | -40.20M | -48.73M | -47.32M | -50.39M | Investing Cash Flow |
| -509.00K | 8.66M | 12.42M | 8.30M | 13.61M | Financing Cash Flow |
| 27.05M | 9.02M | 31.63M | 43.23M | 11.63M |
Accelerate Diagnostics Technical Analysis
Negative
0.51
Price Trends
0.85
Negative
1.04
Negative
1.35
Negative
Market Momentum
-0.09
Negative
27.24
Positive
14.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXDX, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.85, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 27.24 is Positive, neither overbought nor oversold. The STOCH value of 14.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AXDX.
Accelerate Diagnostics Risk Analysis
Accelerate Diagnostics disclosed 52 risk factors in its most recent earnings report. Accelerate Diagnostics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Accelerate Diagnostics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $19.29M | 267.65 | 0.87% | ― | -0.53% | ― | |
54 Neutral | $21.16M | ― | -121.65% | ― | -0.71% | -169.29% | |
53 Neutral | $17.87M | 8.31 | 9.23% | ― | 32.90% | 262.22% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
46 Neutral | $16.08M | ― | -266.25% | ― | 8.91% | 70.18% | |
40 Underperform | $6.14M | ― | 422.38% | ― | -95.07% | 40.41% | |
34 Underperform | $12.86M | ― | 110.26% | ― | -2.99% | 59.87% |
* Healthcare Sector Average
Performance Comparison
AXDX
Accelerate Diagnostics
0.51
-0.41
-44.57%
AMS
American Shared Hospital Services
2.79
-0.18
-6.06%
PTN
Palatin Technologies
0.22
-1.89
-89.57%
IPA
ImmunoPrecise Antibodies
0.46
-0.82
-64.06%
NEPH
Nephros
1.90
-0.30
-13.64%
VVOS
Vivos Therapeutics
2.73
0.10
3.80%
Accelerate Diagnostics Earnings Call Summary
Earnings Call Date:Mar 21, 2025
(Q3-2024)
| % Change Since: -54.87%|
Next Earnings Date:May 08, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed view with several positive achievements such as progress in clinical trials, FDA clearance for new systems, and improved gross margins. However, these were balanced by challenges like decreased net sales and ongoing net losses. The strategic focus on innovation and market leadership is promising, yet financial metrics indicate areas needing attention.Q3-2024 Updates
Positive Updates
Clinical Trial Progress for WAVE System
The clinical trial for the WAVE system and Gram-Negative testing menu is on track with external site enrollments meeting expectations. Submission to the FDA is anticipated in Q1 of 2025 with a review timeline of approximately 9 months.
FDA 510(k) Clearance Obtained for Arc System
The Arc system, which includes the blood culture kit, received FDA 510(k) clearance. This platform is designed to reduce diagnostic turnaround times in clinical settings, especially for conditions like sepsis.
Increased Gross Margin
Gross margin was approximately 29% for the quarter, a significant increase from approximately 3% in the same period in the prior year. This was driven by product mix and an inventory write-down in the prior period.
Reduction in SG&A and R&D Expenses
SG&A expenses were reduced to approximately $5.6 million from $7.8 million, and R&D expenses were reduced to $3.8 million from $7 million compared to the same period in the prior year.
Strong Reduction in Cash Used
Cash used for the quarter was approximately $5.5 million, with a strong reduction in cash used from operations down over $2 million quarter-over-quarter.
Negative Updates
Decrease in Net Sales
Net sales were approximately $3 million for the quarter, down from approximately $3.3 million for the same period in the prior year, primarily due to lower instrument sales.
Ongoing Net Loss
The net loss for the quarter was approximately $14.6 million, resulting in a loss per share of $0.59.
Company Guidance
In the third quarter of 2024, Accelerate Diagnostics, Inc. demonstrated significant advancements and provided detailed guidance on their strategic initiatives. The company reported net sales of approximately $3 million, a slight decrease from $3.3 million the previous year, but saw a high single-digit increase in consumable-related product sales. Gross margin improved to 29% from 3% due to favorable product mix and inventory adjustments. Selling, general, and administrative expenses were reduced to $5.6 million, with research and development expenses also decreasing to $3.8 million, reflecting a focus on lower third-party development costs for the WAVE program. The company's net loss was reported at $14.6 million, equating to a loss per share of $0.59. Despite these financial metrics, Accelerate Diagnostics highlighted strong progress in the clinical trial of their WAVE system, on track for FDA submission in Q1 2025 with a review timeline of approximately nine months. Additionally, their recent FDA 510(k) clearance for the Accelerate Arc system marked a pivotal achievement, promising reduced diagnostic turnaround times and improved antimicrobial stewardship, while their commercial strategy aims to secure long-term contracts and expand market reach beyond the U.S. and EMEA regions. The company maintains a cash burn target of $5 million per quarter, anticipating sufficient operating cash through the end of 2025, contingent upon third-party product partnership payments.Accelerate Diagnostics Corporate Events
Executive/Board Changes
Accelerate Diagnostics CEO Retention Bonus Agreement
Neutral
Apr 25, 2025
On April 22, 2025, Accelerate Diagnostics, Inc. announced a retention bonus agreement with its CEO, Jack Phillips, entitling him to a $200,000 bonus. This agreement requires repayment if his employment ends within 180 days, impacting the company’s leadership stability and potentially influencing investor confidence.
Spark’s Take on AXDX Stock
According to Spark, TipRanks’ AI Analyst, AXDX is a Underperform.
Accelerate Diagnostics faces significant financial challenges with declining revenues, high leverage, and negative cash flow. Technical indicators show bearish momentum, and valuation metrics highlight substantial risk. These factors collectively indicate a high-risk investment with little upside potential.
To see Spark’s full report on AXDX stock, click here.
Executive/Board ChangesBusiness Operations and Strategy
Accelerate Diagnostics Appoints New Independent Directors
Neutral
Apr 15, 2025
On April 10, 2025, Accelerate Diagnostics, Inc. appointed Paul Shalhoub and Gilbert Nathan as independent directors to its Board, with Nathan proposed by certain note holders. The Board also formed a special committee to explore strategic alternatives to maximize value, involving key stakeholders in the process. Additionally, on April 11, 2025, the Board approved retention bonuses for CFO David Patience and CTO Lawrence Mertz, with specific conditions attached to the bonuses.
Spark’s Take on AXDX Stock
According to Spark, TipRanks’ AI Analyst, AXDX is a Underperform.
Accelerate Diagnostics is facing significant financial challenges, with declining revenues, high liabilities, and ongoing losses. Despite some positive developments in their clinical trials and FDA approvals, the stock remains under pressure due to bearish technical indicators and a weak valuation. The company’s ability to turn around its financial performance will be crucial for future stock performance.
To see Spark’s full report on AXDX stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.